US 12,012,439 B2
Treatment of muscular dystrophies
John George Dickson, Egham (GB); and Linda Popplewell, Egham (GB)
Assigned to Royal Holloway and Bedford New College, Surrey (GB)
Filed by Royal Holloway And Bedford New College, Surrey (GB)
Filed on Jun. 21, 2023, as Appl. No. 18/212,244.
Application 18/212,244 is a continuation of application No. 16/770,358, granted, now 11,725,032, previously published as PCT/GB2018/053521, filed on Dec. 5, 2018.
Claims priority of application No. 1720224 (GB), filed on Dec. 5, 2017.
Prior Publication US 2023/0391840 A1, Dec. 7, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/47 (2006.01); C12N 15/86 (2006.01)
CPC C07K 14/4707 (2013.01) [C12N 15/86 (2013.01); C12N 2750/14141 (2013.01)] 26 Claims
OG exemplary drawing
 
1. A method of treating muscular dystrophy, the method comprising administering a therapeutically effective amount of a nucleic acid molecule encoding a functional dystrophin protein to a patient suffering from a muscular dystrophy, wherein the nucleic acid molecule comprises a first nucleotide sequence that has at least 94% identity to the sequence of SEQ ID NO: 1.